Analystreport

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com